Reuters logo
6 months ago
BRIEF-Axovant sciences says exploring nelotanserin as treatment for Rem sleep behavior disorder
February 13, 2017 / 12:23 PM / 6 months ago

BRIEF-Axovant sciences says exploring nelotanserin as treatment for Rem sleep behavior disorder

Feb 13 (Reuters) - Axovant Sciences Ltd

* Axovant sciences announces preliminary results from interim analysis of phase 2 study testing investigational drug nelotanserin in Lewy body dementia patients

* Axovant expects to initiate phase 3 program in second half of 2017

* Plans to expand study recruitment to further explore updrs findings and expects final results in mid-2017

* Axovant Sciences-in interim analysis, secondary endpoints did not demonstrate statistically significant differences for nelotanserin relative to placebo

* Axovant Sciences-is exploring nelotanserin as a potential treatment for rem sleep behavior disorder (RBD) in patients with dementia with Lewy bodies Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below